30 results
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
and ALS recruitment DOWNSTREAM APPROACHES (C3/C5) Do not block ongoing inflammatory pressure of upstream classical pathway C3a C3 C3b More susceptible … components initiating local activation of complement leading to inflammation, recruitment of immune cells, and damage to nerves Rapid onset of action
8-K
EX-99.1
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
to autoantibodies on nerve components initiating local activation of complement leading to inflammation, recruitment of immune cells, and damage to nerves … Classical Pathway Activity Selectively stops upstream & downstream inflammation driven by classical pathway Immune Cell C4b C4a C4 Recruitment Stops
8-K
EX-99.2
opt9r27
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
b9kp076otvdkk
10 Jan 22
Regulation FD Disclosure
6:40am
10-K
55x8uo48
25 Mar 21
Annual report
7:16am